Nothing Special   »   [go: up one dir, main page]

ES2325344B1 - Inhibidores de angiogenesis multifuncionales y multivalentes. - Google Patents

Inhibidores de angiogenesis multifuncionales y multivalentes. Download PDF

Info

Publication number
ES2325344B1
ES2325344B1 ES200402635A ES200402635A ES2325344B1 ES 2325344 B1 ES2325344 B1 ES 2325344B1 ES 200402635 A ES200402635 A ES 200402635A ES 200402635 A ES200402635 A ES 200402635A ES 2325344 B1 ES2325344 B1 ES 2325344B1
Authority
ES
Spain
Prior art keywords
multifunctional
angiogenesis inhibitors
multivalent
angiogenesis
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES200402635A
Other languages
English (en)
Other versions
ES2325344A1 (es
Inventor
Vallina Luis Alvarez
Lobo Victor Javier Sanchez-Arevalo
Martinez Angel Cuesta
Alcober Laura Sanz
Nunez Juan Vargas
Grau Marta Compte
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad Autonoma de Madrid
Original Assignee
Universidad Autonoma de Madrid
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES200402635A priority Critical patent/ES2325344B1/es
Application filed by Universidad Autonoma de Madrid filed Critical Universidad Autonoma de Madrid
Priority to AT05806365T priority patent/ATE454454T1/de
Priority to JP2007539527A priority patent/JP2008527974A/ja
Priority to CA002585282A priority patent/CA2585282A1/en
Priority to ES05806365T priority patent/ES2339366T3/es
Priority to PT05806365T priority patent/PT1814993E/pt
Priority to US11/718,390 priority patent/US20070253952A1/en
Priority to BRPI0517928-9A priority patent/BRPI0517928A/pt
Priority to CN2005800381233A priority patent/CN101065486B/zh
Priority to PCT/EP2005/011714 priority patent/WO2006048252A1/en
Priority to RU2007120521/13A priority patent/RU2398878C2/ru
Priority to DE602005018812T priority patent/DE602005018812D1/de
Priority to EP05806365A priority patent/EP1814993B1/en
Priority to AU2005300737A priority patent/AU2005300737B2/en
Publication of ES2325344A1 publication Critical patent/ES2325344A1/es
Application granted granted Critical
Publication of ES2325344B1 publication Critical patent/ES2325344B1/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES200402635A 2004-11-02 2004-11-02 Inhibidores de angiogenesis multifuncionales y multivalentes. Expired - Lifetime ES2325344B1 (es)

Priority Applications (14)

Application Number Priority Date Filing Date Title
ES200402635A ES2325344B1 (es) 2004-11-02 2004-11-02 Inhibidores de angiogenesis multifuncionales y multivalentes.
RU2007120521/13A RU2398878C2 (ru) 2004-11-02 2005-10-31 Многофункциональные и поливалентные ингибиторы ангиогенеза
CA002585282A CA2585282A1 (en) 2004-11-02 2005-10-31 Multifunctional and multivalent angiogenesis inhibitors
ES05806365T ES2339366T3 (es) 2004-11-02 2005-10-31 Inhibidores de angiogenesis multifuncionales y multivalentes.
PT05806365T PT1814993E (pt) 2004-11-02 2005-10-31 Inibidores de angiogénese multifuncionais e multivalentes
US11/718,390 US20070253952A1 (en) 2004-11-02 2005-10-31 Multifunctional and Multivalent Angiogenesis Inhibitors
BRPI0517928-9A BRPI0517928A (pt) 2004-11-02 2005-10-31 inibidores multifuncionais e multivalentes de angiogênese
CN2005800381233A CN101065486B (zh) 2004-11-02 2005-10-31 多功能和多价的血管生成抑制剂
AT05806365T ATE454454T1 (de) 2004-11-02 2005-10-31 Multifunktionelle und multivalente angiogenese- inhibitoren
JP2007539527A JP2008527974A (ja) 2004-11-02 2005-10-31 多機能性多価血管新生阻害薬
DE602005018812T DE602005018812D1 (de) 2004-11-02 2005-10-31 Multifunktionelle und multivalente angiogenese-inhibitoren
EP05806365A EP1814993B1 (en) 2004-11-02 2005-10-31 Multifunctional and multivalent angiogenesis inhibitors
AU2005300737A AU2005300737B2 (en) 2004-11-02 2005-10-31 Multifunctional and multivalent angiogenesis inhibitors
PCT/EP2005/011714 WO2006048252A1 (en) 2004-11-02 2005-10-31 Multifunctional and multivalent angiogenesis inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200402635A ES2325344B1 (es) 2004-11-02 2004-11-02 Inhibidores de angiogenesis multifuncionales y multivalentes.

Publications (2)

Publication Number Publication Date
ES2325344A1 ES2325344A1 (es) 2009-09-01
ES2325344B1 true ES2325344B1 (es) 2010-06-09

Family

ID=35592070

Family Applications (2)

Application Number Title Priority Date Filing Date
ES200402635A Expired - Lifetime ES2325344B1 (es) 2004-11-02 2004-11-02 Inhibidores de angiogenesis multifuncionales y multivalentes.
ES05806365T Active ES2339366T3 (es) 2004-11-02 2005-10-31 Inhibidores de angiogenesis multifuncionales y multivalentes.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES05806365T Active ES2339366T3 (es) 2004-11-02 2005-10-31 Inhibidores de angiogenesis multifuncionales y multivalentes.

Country Status (13)

Country Link
US (1) US20070253952A1 (es)
EP (1) EP1814993B1 (es)
JP (1) JP2008527974A (es)
CN (1) CN101065486B (es)
AT (1) ATE454454T1 (es)
AU (1) AU2005300737B2 (es)
BR (1) BRPI0517928A (es)
CA (1) CA2585282A1 (es)
DE (1) DE602005018812D1 (es)
ES (2) ES2325344B1 (es)
PT (1) PT1814993E (es)
RU (1) RU2398878C2 (es)
WO (1) WO2006048252A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8580755B2 (en) * 2008-02-19 2013-11-12 University Of Rochester Methods and compositions for treating inflammatory conditions
TW201012473A (en) * 2008-09-22 2010-04-01 Tty Biopharm Co Ltd Composition of inhibiting pathological angiogenesis
WO2010122181A1 (es) * 2009-04-20 2010-10-28 Universidad Autónoma de Madrid Proteínas oligoméricas y sus aplicaciones
US9503931B2 (en) 2009-08-12 2016-11-22 Qualcomm Incorporated Enhancements to the MU-MIMO VHT preamble to enable mode detection
WO2011076095A1 (en) * 2009-12-21 2011-06-30 Tty Biopharm Company Limited Methods and compositions related to reduced met phosphorylation by leukocyte cell-derived chemotaxin 2 in tumor cells
EP2420253A1 (en) 2010-08-20 2012-02-22 Leadartis, S.L. Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
WO2012049328A1 (en) 2010-10-15 2012-04-19 Leadartis, S.L. Generation of multifunctional and multivalent polypeptide complexes with collagen xviii trimerization domain
EP2441776A1 (en) 2010-10-15 2012-04-18 Leadartis, S.L. Generation of multifunctional and multivalent polypeptide complexes with collagen XVIII trimerization domain
EP2561888A1 (en) * 2011-08-23 2013-02-27 Deutsches Krebsforschungszentrum Protein comprising NC-1 for treating angiogenesis-related diseases
KR102155875B1 (ko) * 2015-06-28 2020-09-16 올제네시스 바이오테라퓨틱스 아이엔씨. 혈관신생 억제용 융합 단백질
CA3177098A1 (en) 2020-06-05 2021-12-09 Pieris Pharmaceuticals Gmbh Multimeric immunomodulator targeting 4-1bb

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010015868A (ko) * 1997-12-08 2001-02-26 베쓰 이스라엘 디코니스 메디칼 센터 피치아 효모 발현계를 사용하여 항혈관형성 단백질인엔도스타틴, 안지오스타틴 또는 레스틴을 생성시키는 방법
PT1107989E (pt) * 1998-08-25 2010-07-02 Merck Patent Gmbh Express†o e exportaã†o de angiostatina e endostatina na forma de imunofusinas
DE19900743A1 (de) * 1999-01-12 2000-07-13 Aventis Pharma Gmbh Neue komplexbildende Proteine
EP1179541B1 (en) * 1999-04-28 2004-06-16 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting VEGF
JP2005530484A (ja) * 2002-02-07 2005-10-13 デルタ バイオテクノロジー リミテッド アルブミン融合抗血管形成ペプチド
US7538088B2 (en) * 2002-04-26 2009-05-26 California Institute Of Technology Method for inhibiting angiogenesis by administration of the extracellular domain of D1-1 polypeptide
WO2004019878A2 (en) * 2002-08-27 2004-03-11 Compound Therapeutics, Inc. Adzymes and uses thereof
US20050008649A1 (en) * 2003-06-02 2005-01-13 University Of Miami Chimeric molecules and methods of use
PL1819359T3 (pl) * 2004-12-09 2015-08-31 Janssen Biotech Inc Immunokoniugaty skierowane przeciw integrynie, metody ich wytwarzania oraz ich zastosowanie

Also Published As

Publication number Publication date
CN101065486A (zh) 2007-10-31
ES2325344A1 (es) 2009-09-01
US20070253952A1 (en) 2007-11-01
CA2585282A1 (en) 2006-05-11
BRPI0517928A (pt) 2008-10-21
AU2005300737A1 (en) 2006-05-11
CN101065486B (zh) 2011-08-31
ES2339366T3 (es) 2010-05-19
AU2005300737B2 (en) 2011-05-19
WO2006048252A1 (en) 2006-05-11
EP1814993B1 (en) 2010-01-06
ATE454454T1 (de) 2010-01-15
JP2008527974A (ja) 2008-07-31
DE602005018812D1 (de) 2010-02-25
RU2398878C2 (ru) 2010-09-10
EP1814993A1 (en) 2007-08-08
PT1814993E (pt) 2010-04-12
RU2007120521A (ru) 2008-12-10

Similar Documents

Publication Publication Date Title
MX2022009947A (es) Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos.
WO2007115837A3 (en) Combination of an anti-edb fibronectin domain antibody/ il2 fusion protein and a further small molecule
NO20080626L (no) Inhibitorer av fibroblastaktiverende protein alfa
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
ES2325344B1 (es) Inhibidores de angiogenesis multifuncionales y multivalentes.
JO3134B1 (ar) مثبطات نشاط akt
CR10273A (es) "anticuerpos anti-5t4 y usos de los mismos"
BR112018068703A2 (pt) inibidores substituídos de menin-mll e métodos de uso
CY1116964T1 (el) Μονοκλωνικα αντισωματα εναντι claudin-18 στην αγωγη εναντι καρκινου
ECSP067014A (es) Modulación de producción de inmunoglobulina y trastornos atópicos
TW200604184A (en) Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
BR112021015092A2 (pt) Proteína de fusão, sistema de rna guia duplo, e, rna guia
EA200801301A1 (ru) ИНГИБИТОРЫ АКТИВНОСТИ Akt
DK1553975T3 (da) Optimerede Fc-varianter og fremgangsmåder til generering heraf.
BRPI0809583A2 (pt) polipeptídeos fgf-21 modificados e seus usos
WO2009009173A3 (en) Klotho-beta for use in treating cancer, liver disorders, gallstones, wasting syndrome and obesity-related diseases
CL2008001234A1 (es) Compuestos derivados de heterociclos nitrogenados, inhibidores de las proteinas de apoptosis; y uso en el tratamiento del cancer.
EA200901313A1 (ru) Ингибиторы тирозинкиназы брутона
EA200870411A1 (ru) Полипептиды с усиленным противовоспалительным и пониженным цитотоксическим свойствами и связанные с ними способы
CL2008003527A1 (es) Conjugado de anticuerpo o porcion de union de antigeno del mismo, que se une a la proteina tirosina quinasa 7 (ptk-7/cck4); composicion que lo comprende; acido nulceico cidificante del anticuerpo; vector y celula huesped; uso del conjugado para tratar o prevenir una enfermedad de celulas tumorales que expresan ptk7
EA200970737A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
NO20082240L (no) GLP-2 imitatorstoff, polypeptider, sammensetninger, fremgangsmater og anvendelser
EA200700717A1 (ru) Сульфонамиды
EA200400235A1 (ru) Комбинированная терапия для лечения рака
NL1024495A1 (nl) Werkwijze voor het verbeteren van de productie van Fischer-Tropsch-destillaatbrandstoffen.

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20090901

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2325344B1

Country of ref document: ES